Total trials
130
Active
13
Phase 3
5
Total enrollment
93,966
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ketamine | — | — | — | — | 3 | ||
| Magnesium sulfate | — | — | — | — | — | 1 | |
| Early TAP Block | — | — | — | — | — | 1 | |
| Late TAP Block | — | — | — | — | — | 1 | |
| Bladder Instillations | — | — | — | — | — | 1 |
Next readouts
- 2026-02-03
- 2026-09
- 2028-08
Top conditions
- Coronary Artery Disease9
- Interstitial Cystitis6
- Urinary Incontinence6
- Overactive Bladder5
- Chest Pain5
- Prostate Cancer5
- Pelvic Pain5
- Coronary Disease4
Frequently asked questions about Corewell Health East
- How many clinical trials does Corewell Health East have on ClinicalTrials.gov?
- Corewell Health East is listed as the lead sponsor on 130 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Corewell Health East's trials are in Phase 3?
- 5 of Corewell Health East's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Corewell Health East focus on?
- Corewell Health East's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Interstitial Cystitis, Urinary Incontinence, Overactive Bladder, Chest Pain.
- When are Corewell Health East's next clinical trial readouts?
- Corewell Health East has 3 upcoming primary-completion readouts tracked here; the soonest is “Bladder Directed vs. Pelvic Floor Therapy in IC/BPS”, expected around 2026-02-03.